Key Insights
- 19 studies across Novartis’ cardiovascular portfolio set to make headlines at ESC 2025, Madrid.
- Breakthrough data on Leqvio, Entresto, pelacarsen, and abelacimab highlight strong pipeline and established therapies.
- Potential to reshape global cardiovascular care, addressing unmet needs from cholesterol reduction to atrial fibrillation
Leqvio: Can Inclisiran’s Expanding Role Become a Game-Changer in Cholesterol Management?
Novartis is spotlighting the VICTORION-Difference study, which compares inclisiran-based therapy against the standard of care, alongside new monotherapy data from China. The findings aim to strengthen Leqvio’s positioning as a next-generation lipid-lowering solution, offering sustained outcomes and easier patient adherence. With cholesterol control being a major unmet challenge globally, this data could push Leqvio further into front-line therapy strategies.
Pelacarsen: Could Reducing Lipoprotein(a) Change the Economics of Cardiovascular Care?
The Lp(a)FRONTIERS APHERESIS trial suggests pelacarsen could significantly reduce the need for apheresis—a costly and invasive cholesterol removal procedure. Alongside real-world evidence on future cardiovascular events and the economic burden of elevated lipoprotein(a), pelacarsen is emerging as a promising candidate to cut both patient risks and healthcare costs.
Entresto: A Step Forward in Addressing Chagas-Driven Heart Failure?
The PARACHUTE-HF trial compares sacubitril/valsartan (Entresto) with enalapril in patients with heart failure caused by chronic Chagas disease—a major unmet need in Latin America. Results could expand Entresto’s global relevance, offering new hope for millions living with this condition while reinforcing its leadership in heart failure therapy.
Abelacimab: Will Factor XI Inhibition Redefine Atrial Fibrillation Treatment Safety?
Early insights from the AZALEA-TIMI 71 program explore abelacimab’s potential in atrial fibrillation patients, with specific focus on bleeding risks and renal function. With anticoagulation therapies often limited by safety concerns, abelacimab could open a new chapter in safer stroke prevention strategies.
ESC 2025: A Global Stage for Cardiovascular Innovation
The European Society of Cardiology (ESC) Congress is the largest gathering of cardiovascular professionals worldwide, attracting thousands of experts, researchers, and industry leaders each year. ESC 2025 in Madrid serves as a critical platform for unveiling cutting-edge science, transformative therapies, and future treatment strategies in heart health. Novartis’ broad presence with 19 presentations underscores both the scale of its cardiovascular ambition and the growing global urgency to address heart disease, which remains the world’s leading cause of mortality.
By